An anti-endoglin antibody is currently being tested in clinical trials in combination with pazopanib for soft tissue sarcoma, with preliminary results in a phase I/II trial showing 2/2 patients with complete response, suggesting efficacy in angiosarcoma that requires further investigation (NCT01975519).75 Here, ENG is linked to angiosarcoma.